Ophthalmic Pathology and Intraocular Tumors

Last major revision 2016–2017
The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Academy of Ophthalmology designates this enduring material for a maximum of 10 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME expiration date: June 1, 2019. AMA PRA Category 1 Credits™ may be claimed only once between June 1, 2016, and the expiration date.

BCSC® volumes are designed to increase the physician's ophthalmic knowledge through study and review. Users of this activity are encouraged to read the text and then answer the study questions provided at the back of the book.

To claim AMA PRA Category 1 Credits™ upon completion of this activity, learners must demonstrate appropriate knowledge and participation in the activity by taking the posttest for Section 4 and achieving a score of 80% or higher. For further details, please see the instructions for requesting CME credit at the back of the book.

The Academy provides this material for educational purposes only. It is not intended to represent the only or best method or procedure in every case, nor to replace a physician's own judgment or give specific advice for case management. Including all indications, contraindications, side effects, and alternative agents for each drug or treatment is beyond the scope of this material. All information and recommendations should be verified, prior to use, with current information included in the manufacturers' package inserts or other independent sources, and considered in light of the patient's condition and history. Reference to certain drugs, instruments, and other products in this course is made for illustrative purposes only and is not intended to constitute an endorsement of such. Some material may include information on applications that are not considered community standard, that reflect indications not included in approved FDA labeling, or that are approved for use only in restricted research settings. The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use, and to use them with appropriate, informed patient consent in compliance with applicable law. The Academy specifically disclaims any and all liability for injury or other damages of any kind, from negligence or otherwise, for any and all claims that may arise from the use of any recommendations or other information contained herein.

AAO, AAOE, American Academy of Ophthalmology, Basic and Clinical Science Course, BCSC, EyeCare America, EyeNet, EyeSmart, EyeWiki, Focal Points, IRIS, ISRS, OKAP, ONE, Ophthalmic Technology Assessments, Ophthalmology, Preferred Practice Pattern, ProVision, SmartSight, The Ophthalmic News & Education Network, and the AAO logo (shown on cover) and tagline (Protecting Sight. Empowering Lives.) are, among other marks, the registered trademarks and trademarks of the American Academy of Ophthalmology.

Cover image: From BCSC Section 5, Neuro-Ophthalmology. Fundus photograph showing an arteriovenous malformation (racemose angioma) of the retina in a patient with Wyburn-Mason syndrome. (Courtesy of Mark J. Greenwald, MD.)

Copyright © 2017 American Academy of Ophthalmology. All rights reserved. No part of this publication may be reproduced without written permission. Printed in the United States of America.
Basic and Clinical Science Course

Louis B. Cantor, MD, Indianapolis, Indiana, Senior Secretary for Clinical Education
Christopher J. Rapuano, MD, Philadelphia, Pennsylvania, Secretary for Lifelong Learning and Assessment
George A. Cioffi, MD, New York, New York, BCSC Course Chair

Section 4

Faculty

Robert H. Rosa Jr, MD, Chair, Temple, Texas
Michele M. Bloomer, MD, San Francisco, California
Dan S. Gombos, MD, Houston, Texas
Tatyana Milman, MD, Philadelphia, Pennsylvania
Heather A.D. Potter, MD, Madison, Wisconsin
Nasreen A. Syed, MD, Iowa City, Iowa
Tero T. Kivelä, MD, Consultant, Helsinki, Finland

The Academy wishes to acknowledge the American Association of Ophthalmic Oncologists and Pathologists for recommending faculty members to the BCSC Section 4 committee.

The Academy also wishes to acknowledge the following committees for review of this edition:

Committee on Aging: Patricia Chévez-Barrios, MD, Houston, Texas
Vision Rehabilitation Committee: Joseph L. Fontenot, MD, Daphne, Alabama

Practicing Ophthalmologists Advisory Committee for Education: Robert G. Fante, MD, Primary Reviewer, Denver, CO; Edward K. Isbey III, Chair, Asheville, North Carolina; Alice Bashinsky, MD, Asheville, North Carolina; David Browning, MD, PhD, Charlotte, North Carolina; Bradley Fouraker, MD, Tampa, Florida; Dasa Gangadhar, MD, Wichita, Kansas; Steven J. Grosser, MD, Golden Valley, Minnesota; Stephen R. Klapper, MD, Carmel, Indiana; James A. Savage, MD, Memphis, Tennessee

European Board of Ophthalmology: Tero T. Kivelä, MD, Chair, Helsinki, Finland; Edoardo Midena, MD, PhD, Liaison, Padua, Italy; Nikolaos E. Bechrakis, MD, FEBO, Innsbruck, Austria; Sarah E. Coupland, MBBS, PhD, FRCPath, Liverpool, United Kingdom; Laurence Desjardins, MD, Paris, France; Steffen Heegaard, MD, DMSc, Copenhagen, Denmark; Elisabeth M. Messmer, MD, PhD, FEBO, Munich, Germany; Fiona Roberts, MBChB, MD, FRCPath, Glasgow, United Kingdom
Financial Disclosures

Academy staff members who contributed to the development of this product state that within the 12 months prior to their contributions to this CME activity and for the duration of development, they have had no financial interest in or other relationship with any entity discussed in this course that produces, markets, resells, or distributes ophthalmic health care goods or services consumed by or used in patients, or with any competing commercial product or service.

The authors and reviewers state that within the 12 months prior to their contributions to this CME activity and for the duration of development, they have had the following financial relationships:

* Dr Bechrakis: Alcon Laboratories (C, S), Bayer (C, S), HOYA (S), Novartis Pharmaceuticals (C)

Dr Browning: Aerpio Therapeutics (S), Alimera Sciences (C), Genentech (S), Novartis Pharmaceuticals (S), Pfizer (S), Regeneron Pharmaceuticals (S)

Dr Fouraker: Addition Technology (C, L), Alcon Laboratories (C, L), KeraVision (C, L), OASIS Medical (C, L)

Dr Grosser: Ivantis (O)

Dr Heegaard: Santen (L), Théa (L)

Dr Isbey: Alcon Laboratories (S), Bausch + Lomb (S)

Dr Messmer: Alcon Pharmaceuticals (C, L), Allergan (C, L), CROMA-PHARMA (C, L), Dompé (C), Théa (C, L), URSAPHARM (L)

Dr Savage: Allergan (L)

Dr Syed: Calvert Laboratories (C)

The other authors and reviewers state that within the past 12 months prior to their contributions to this CME activity and for the duration of development, they have had no financial interest in or other relationship with any entity discussed in this course that produces, markets, resells, or distributes ophthalmic health care goods or services consumed by or used in patients, or with any competing commercial product or service.

*C = consultant fees, paid advisory boards, or fees for attending a meeting; L = lecture fees (honoraria), travel fees, or reimbursements when speaking at the invitation of a commercial sponsor; O = equity ownership/stock options of publicly or privately traded firms (excluding mutual funds) with manufacturers of commercial ophthalmic products or commercial ophthalmic services; P = patents and/or royalties that might be viewed as creating a potential conflict of interest; S = grant support for the past year (all sources) and all sources used for a specific talk or manuscript with no time limitation

Recent Past Faculty

Ronald Buggage, MD
George J. Harocopos, MD
Theresa Retue Kramer, MD
Jacob Pe'er, MD
Ron W. Pelton, MD, PhD
Matthew W. Wilson, MD
In addition, the Academy gratefully acknowledges the contributions of numerous past faculty and advisory committee members who have played an important role in the development of previous editions of the Basic and Clinical Science Course.

**American Academy of Ophthalmology Staff**

Dale E. Fajardo, *Vice President, Education*
Beth Wilson, *Director, Continuing Professional Development*
Ann McGuire, *Acquisitions and Development Manager*
Stephanie Tanaka, *Publications Manager*
D. Jean Ray, *Production Manager*
Kimberly Torgerson, *Publications Editor*
Beth Collins, *Medical Editor*
Naomi Ruiz, *Publications Specialist*
Contents

General Introduction ................................................. xv

Objectives ......................................................... 1

PART I  Ophthalmic Pathology ..................................... 3

1 Introduction to Part I ........................................... 5
   Organization ..................................................... 6
   Topography ..................................................... 6
   Disease Process .............................................. 6
   General Diagnosis ........................................... 11
   Differential Diagnosis ..................................... 11

2 Wound Repair ................................................... 13
   General Aspects of Wound Repair ......................... 13
   Healing in Specific Ocular Tissues ....................... 13
      Cornea ..................................................... 13
      Sclera ..................................................... 16
      Uvea ....................................................... 16
      Lens ......................................................... 17
      Retina ...................................................... 17
      Vitreous .................................................... 17
      Eyelid, Orbit, and Lacrimal Tissues ................. 17
   Histologic Sequelae of Ocular Trauma ................... 17

3 Specimen Handling ............................................... 25
   Communication ............................................... 25
   Fixatives for Tissue Preservation ....................... 26
   Orientation .................................................... 27
   Gross Dissection ............................................. 28
   Processing and Staining .................................. 30
      Tissue Processing ........................................ 30
      Tissue Staining and Slide Preparation ............. 30

4 Special Procedures .............................................. 33
   Immunohistochemistry ..................................... 33
   Flow Cytometry, Molecular Pathology, and Diagnostic
      Electron Microscopy ....................................... 36
      Flow Cytometry .......................................... 36
      Molecular Pathology ..................................... 36
      Diagnostic Electron Microscopy ...................... 42
## Contents

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Special Techniques</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td>Fine-Needle Aspiration Biopsy</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td>Frozen Section</td>
<td>43</td>
</tr>
<tr>
<td>5</td>
<td><strong>Conjunctiva</strong></td>
<td>47</td>
</tr>
<tr>
<td></td>
<td>Topography</td>
<td>47</td>
</tr>
<tr>
<td></td>
<td>Congenital Anomalies</td>
<td>47</td>
</tr>
<tr>
<td></td>
<td>Choristomas</td>
<td>47</td>
</tr>
<tr>
<td></td>
<td>Hamartomas</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>Inflammations</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>Papillary Versus Follicular Conjunctivitis</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>Granulomatous Conjunctivitis</td>
<td>51</td>
</tr>
<tr>
<td></td>
<td>Infectious Conjunctivitis</td>
<td>52</td>
</tr>
<tr>
<td></td>
<td>Noninfectious Conjunctivitis</td>
<td>53</td>
</tr>
<tr>
<td></td>
<td>Pyogogenic Granuloma (Exuberant Granulation Tissue)</td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>Degenerations</td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>Pinguecula and Pterygium</td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>Amyloid Deposits</td>
<td>58</td>
</tr>
<tr>
<td></td>
<td>Epithelial Inclusion Cyst</td>
<td>59</td>
</tr>
<tr>
<td></td>
<td>Neoplasia</td>
<td>59</td>
</tr>
<tr>
<td></td>
<td>Squamous Lesions</td>
<td>59</td>
</tr>
<tr>
<td></td>
<td>Melanocytic Lesions</td>
<td>61</td>
</tr>
<tr>
<td></td>
<td>Lymphoid Lesions</td>
<td>69</td>
</tr>
<tr>
<td></td>
<td>Glandular Lesions</td>
<td>71</td>
</tr>
<tr>
<td></td>
<td>Other Neoplasms</td>
<td>72</td>
</tr>
<tr>
<td>6</td>
<td><strong>Cornea</strong></td>
<td>73</td>
</tr>
<tr>
<td></td>
<td>Topography</td>
<td>73</td>
</tr>
<tr>
<td></td>
<td>Congenital Anomalies</td>
<td>73</td>
</tr>
<tr>
<td></td>
<td>Dermoid</td>
<td>73</td>
</tr>
<tr>
<td></td>
<td>Peters Anomaly</td>
<td>74</td>
</tr>
<tr>
<td></td>
<td>Inflammations</td>
<td>75</td>
</tr>
<tr>
<td></td>
<td>Infectious Keratitis</td>
<td>75</td>
</tr>
<tr>
<td></td>
<td>Noninfectious Keratitis</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>Degenerations and Dystrophies</td>
<td>81</td>
</tr>
<tr>
<td></td>
<td>Degenerations</td>
<td>81</td>
</tr>
<tr>
<td></td>
<td>Dystrophies</td>
<td>86</td>
</tr>
<tr>
<td></td>
<td>Ectatic Disorders</td>
<td>95</td>
</tr>
<tr>
<td></td>
<td>Keratoconus</td>
<td>95</td>
</tr>
<tr>
<td></td>
<td>Neoplasia</td>
<td>96</td>
</tr>
<tr>
<td>7</td>
<td><strong>Anterior Chamber and Trabecular Meshwork</strong></td>
<td>97</td>
</tr>
<tr>
<td></td>
<td>Topography</td>
<td>97</td>
</tr>
<tr>
<td></td>
<td>Congenital Anomalies</td>
<td>98</td>
</tr>
<tr>
<td></td>
<td>Primary Congenital Glaucoma</td>
<td>98</td>
</tr>
<tr>
<td></td>
<td>Anterior Segment Dysgenesis</td>
<td>98</td>
</tr>
<tr>
<td>Section</td>
<td>Page</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>------</td>
<td></td>
</tr>
<tr>
<td>Degenerations</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>Iridocorneal Endothelial Syndrome</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>Secondary Glaucoma</td>
<td>101</td>
<td></td>
</tr>
<tr>
<td>Neoplasia</td>
<td>106</td>
<td></td>
</tr>
<tr>
<td><strong>Sclera</strong></td>
<td>107</td>
<td></td>
</tr>
<tr>
<td>Topography</td>
<td>107</td>
<td></td>
</tr>
<tr>
<td>Congenital Anomalies</td>
<td>108</td>
<td></td>
</tr>
<tr>
<td>Choristoma</td>
<td>108</td>
<td></td>
</tr>
<tr>
<td>Nanophthalmos</td>
<td>108</td>
<td></td>
</tr>
<tr>
<td>Microphthalmos</td>
<td>109</td>
<td></td>
</tr>
<tr>
<td>Inflammations</td>
<td>109</td>
<td></td>
</tr>
<tr>
<td>Episcleritis</td>
<td>109</td>
<td></td>
</tr>
<tr>
<td>Scleritis</td>
<td>109</td>
<td></td>
</tr>
<tr>
<td>Degenerations</td>
<td>111</td>
<td></td>
</tr>
<tr>
<td>Senile Calcific Plaque</td>
<td>111</td>
<td></td>
</tr>
<tr>
<td>Scleral Staphyloma</td>
<td>111</td>
<td></td>
</tr>
<tr>
<td>Neoplasia</td>
<td>112</td>
<td></td>
</tr>
<tr>
<td>Fibrous Histiocytoma</td>
<td>112</td>
<td></td>
</tr>
<tr>
<td>Nodular Fasciitis</td>
<td>112</td>
<td></td>
</tr>
<tr>
<td><strong>Lens</strong></td>
<td>115</td>
<td></td>
</tr>
<tr>
<td>Topography</td>
<td>115</td>
<td></td>
</tr>
<tr>
<td>Capsule</td>
<td>115</td>
<td></td>
</tr>
<tr>
<td>Epithelium</td>
<td>117</td>
<td></td>
</tr>
<tr>
<td>Cortex and Nucleus</td>
<td>117</td>
<td></td>
</tr>
<tr>
<td>Zonular Fibers</td>
<td>117</td>
<td></td>
</tr>
<tr>
<td>Congenital Anomalies</td>
<td>117</td>
<td></td>
</tr>
<tr>
<td>Congenital Aphakia</td>
<td>117</td>
<td></td>
</tr>
<tr>
<td>Anterior Lenticus and Lentiglobus</td>
<td>118</td>
<td></td>
</tr>
<tr>
<td>Posterior Lenticus (Lentiglobus)</td>
<td>118</td>
<td></td>
</tr>
<tr>
<td>Inflammations</td>
<td>118</td>
<td></td>
</tr>
<tr>
<td>Phacoantigenic Uveitis</td>
<td>118</td>
<td></td>
</tr>
<tr>
<td>Propionibacterium acnes Endophthalmitis</td>
<td>119</td>
<td></td>
</tr>
<tr>
<td>Degenerations</td>
<td>120</td>
<td></td>
</tr>
<tr>
<td>Cataract and Other Abnormalities</td>
<td>120</td>
<td></td>
</tr>
<tr>
<td>Neoplasia and Associations With Systemic Disorders</td>
<td>124</td>
<td></td>
</tr>
<tr>
<td>Pathology in Intraocular Lenses</td>
<td>124</td>
<td></td>
</tr>
<tr>
<td><strong>Vitreous</strong></td>
<td>125</td>
<td></td>
</tr>
<tr>
<td>Topography</td>
<td>125</td>
<td></td>
</tr>
<tr>
<td>Congenital Anomalies</td>
<td>125</td>
<td></td>
</tr>
<tr>
<td>Persistent Fetal Vasculature</td>
<td>125</td>
<td></td>
</tr>
<tr>
<td>Bergmeister Papilla</td>
<td>126</td>
<td></td>
</tr>
<tr>
<td>Mittendorf Dot</td>
<td>126</td>
<td></td>
</tr>
<tr>
<td>Vitreous Cysts</td>
<td>126</td>
<td></td>
</tr>
<tr>
<td>Inflammations</td>
<td>127</td>
<td></td>
</tr>
</tbody>
</table>
11 Retina and Retinal Pigment Epithelium ........................................ 139
   Topography ...................................................................................... 139
      Neurosensory Retina ..................................................................... 139
      Retinal Pigment Epithelium .......................................................... 141
   Congenital Anomalies ....................................................................... 142
      Albinism .......................................................................................... 142
      Myelinated Nerve Fibers ................................................................. 143
      Vascular Anomalies ........................................................................ 143
      Congenital Hypertrophy of the RPE ................................................. 144
   Inflammations .................................................................................... 145
      Infectious .......................................................................................... 145
      Noninfectious .................................................................................. 148
   Degenerations ................................................................................... 148
      Typical and Reticular Peripheral Cystoid Degeneration 
      and Retinoschisis ......................................................................... 148
      Lattice Degeneration ....................................................................... 148
      Paving-Stone Degeneration .............................................................. 150
      Ischemia ......................................................................................... 150
      Age-Related Macular Degeneration ............................................... 160
      Polypoidal Choroidal Vasculopathy ............................................... 166
      Macular Dystrophies ....................................................................... 168
      Diffuse Photoreceptor Dystrophies .................................................. 170
   Neoplasia ............................................................................................ 172
      Retinoblastoma .............................................................................. 172
      Retinocytoma .................................................................................. 178
      Medulloepithelioma ........................................................................ 178
      Fuchs Adenoma .............................................................................. 179
      Combined Hamartoma of the Retina and RPE ................................. 179
      Adenomas and Adenocarcinomas of the RPE ................................. 180

12 Uveal Tract ....................................................................................... 181
   Topography ....................................................................................... 181
   Iris ....................................................................................................... 181
   Ciliary Body ....................................................................................... 182
   Choroid ............................................................................................... 182
   Congenital Anomalies ....................................................................... 184
      Aniridia ............................................................................................. 184
      Coloboma ....................................................................................... 184
Inflammations ......................................................... 185
  Infectious ......................................................... 185
  Noninfectious ..................................................... 185
Degenerations ........................................................ 188
  Rubeosis Iridis .................................................... 188
  Hyalinization of the Ciliary Body .............................. 188
  Choroidal Neovascularization .................................. 188
Neoplasia ............................................................ 189
  Iris ................................................................. 189
  Choroid and Ciliary Body ........................................ 191
  Metastatic Tumors ............................................... 197
  Other Uveal Tumors .............................................. 197

13 Eyelids ............................................................ 201
  Topography ......................................................... 201
  Congenital Anomalies ............................................ 202
    Distichiasis .................................................... 202
    Phakomatous Choristoma ...................................... 202
    Congenital Dermoid Cyst ...................................... 203
Inflammations ....................................................... 203
  Infectious ......................................................... 203
  Noninfectious ..................................................... 204
Degenerations ........................................................ 206
  Xanthelasma ...................................................... 206
  Amyloidosis ...................................................... 206
Cysts ................................................................. 208
  Epidermoid Cysts ................................................ 208
  Ductal Cysts ...................................................... 208
Neoplasia ............................................................ 209
  Epidermal Neoplasms ............................................ 209
  Dermal Neoplasms ............................................... 214
  Neoplasms and Proliferations of the Dermal Appendages .. 214
  Melanocytic Neoplasms .......................................... 218

14 Orbit .............................................................. 223
  Topography ......................................................... 223
  Bony Orbit and Soft Tissues .................................... 223
  Congenital Anomalies ............................................ 223
    Cysts ............................................................. 223
Inflammations ....................................................... 224
  Noninfectious ..................................................... 224
  Infectious ......................................................... 224
Degenerations ....................................................... 226
  Amyloid ............................................................. 228
  Neoplasia .......................................................... 228
  Lacrimal Sac Neoplasia .......................................... 229
  Lacrimal Gland Neoplasia ....................................... 229
Lymphoproliferative Lesions ............................................. 231
Soft-Tissue Tumors ..................................................... 233
Vascular Tumors ......................................................... 233
Tumors With Fibrous Differentiation ................................ 235
Tumors With Muscle Differentiation ............................... 236
Nerve Sheath Tumors ................................................... 237
Adipose Tumors .......................................................... 238
Bony Lesions of the Orbit .............................................. 239
Secondary Tumors ....................................................... 240

15 Optic Nerve ............................................................ 241
  Topography ............................................................. 241
  Congenital Anomalies ................................................. 241
    Colobomas .......................................................... 242
  Inflammations ......................................................... 243
    Infectious ............................................................ 243
    Noninfectious ....................................................... 244
  Degenerations ......................................................... 245
    Optic Atrophy ...................................................... 245
    Drusen ............................................................... 247
  Neoplasia .............................................................. 248
    Melanocytoma ...................................................... 248
    Glioma ............................................................... 249
    Meningioma ........................................................ 250

PART II Intraocular Tumors: Clinical Aspects ................... 251

16 Introduction to Part II .............................................. 253

17 Melanocytic Tumors ............................................... 255
  Introduction .......................................................... 255
  Iris Nevus ............................................................. 255
  Nevus of the Ciliary Body and Choroid ........................ 256
  Melanocytoma of the Iris, Ciliary Body, and Choroid ....... 258
  Iris Melanoma ........................................................ 258
  Melanoma of the Ciliary Body and Choroid .................... 262
    Clinical Characteristics ......................................... 262
    Diagnostic Evaluation ........................................... 264
    Differential Diagnosis .......................................... 267
    Classification ..................................................... 271
    Metastatic Evaluation ........................................... 272
    Treatment ........................................................... 274
    Prognosis and Prognostic Factors ............................... 277
  Pigmented Epithelial Tumors of the Uvea and Retina ....... 279
    Adenoma and Adenocarcinoma ................................... 279
    Acquired Hyperplasia ............................................. 279
    Simple Hamartoma ............................................... 279
    Combined Hamartoma ............................................. 280
## Contents

18 **Angiomatous Tumors** ........................................ 281
   Hemangiomas .................................................. 281
   Choroidal Hemangiomas .................................... 281
   Retinal Angiomas ............................................ 283
   Arteriovenous Malformations ............................... 286

19 **Retinoblastoma** .............................................. 289
   Genetic Counseling .......................................... 289
   Diagnostic Evaluation ........................................ 291
   Clinical Examination ........................................ 291
   Differential Diagnosis ....................................... 294
   Classification ................................................ 297
   Associated Conditions ....................................... 298
   Retinoblastoma ............................................... 298
   Primitive Neuroectodermal Tumor ......................... 298
   Treatment ...................................................... 299
   Enucleation ................................................... 299
   Chemotherapy .................................................. 299
   Laser Therapy Including Transpupillary Thermotherapy .. 300
   Cryotherapy .................................................... 300
   External-Beam Radiation Therapy .......................... 301
   Plaque Radiotherapy (Brachytherapy) ...................... 301
   Prospective Trials ............................................ 301
   Spontaneous Regression ...................................... 301
   Prognosis ....................................................... 302

20 **Ocular Involvement in Systemic Malignancies** ............. 303
   Secondary Tumors of the Eye ................................ 303
   Metastatic Carcinoma ......................................... 303
   Direct Intraocular Extension ................................. 310
   Lymphomatous Tumors ....................................... 311
   Primary Intraocular Lymphoma ............................... 311
   Uveal Lymphoproliferative Lesions ....................... 313
   Secondary Involvement of Systemic Lymphoma .......... 314
   Ocular Manifestations of Leukemia ....................... 315

   Basic Texts ................................................... 317
   Related Academy Materials .................................. 319
   Requesting Continuing Medical Education Credit ....... 321
   Study Questions .............................................. 323
   Answer Sheet for Section 4 Study Questions ............ 333
   Answers ....................................................... 335
   Index .......................................................... 343
General Introduction

The Basic and Clinical Science Course (BCSC) is designed to meet the needs of residents and practitioners for a comprehensive yet concise curriculum of the field of ophthalmology. The BCSC has developed from its original brief outline format, which relied heavily on outside readings, to a more convenient and educationally useful self-contained text. The Academy updates and revises the course annually, with the goals of integrating the basic science and clinical practice of ophthalmology and of keeping ophthalmologists current with new developments in the various subspecialties.

The BCSC incorporates the effort and expertise of more than 90 ophthalmologists, organized into 13 Section faculties, working with Academy editorial staff. In addition, the course continues to benefit from many lasting contributions made by the faculties of previous editions. Members of the Academy Practicing Ophthalmologists Advisory Committee for Education, Committee on Aging, and Vision Rehabilitation Committee review every volume before major revisions. Members of the European Board of Ophthalmology, organized into Section faculties, also review each volume before major revisions, focusing primarily on differences between American and European ophthalmology practice.

Organization of the Course

The Basic and Clinical Science Course comprises 13 volumes, incorporating fundamental ophthalmic knowledge, subspecialty areas, and special topics:

1. Update on General Medicine
2. Fundamentals and Principles of Ophthalmology
3. Clinical Optics
4. Ophthalmic Pathology and Intraocular Tumors
5. Neuro-Ophthalmology
6. Pediatric Ophthalmology and Strabismus
7. Orbit, Eyelids, and Lacrimal System
8. External Disease and Cornea
9. Intraocular Inflammation and Uveitis
10. Glaucoma
11. Lens and Cataract
12. Retina and Vitreous
13. Refractive Surgery

In addition, a comprehensive Master Index allows the reader to easily locate subjects throughout the entire series.

References

Readers who wish to explore specific topics in greater detail may consult the references cited within each chapter and listed in the Basic Texts section at the back of the book.
Study Questions and CME Credit

Each volume of the BCSC is designed as an independent study activity for ophthalmology residents and practitioners. The learning objectives for this volume are given on page 1. The text, illustrations, and references provide the information necessary to achieve the objectives; the study questions allow readers to test their understanding of the material and their mastery of the objectives. Physicians who wish to claim CME credit for this educational activity may do so by following the instructions given at the end of the book.

Conclusion

The Basic and Clinical Science Course has expanded greatly over the years, with the addition of much new text, numerous illustrations, and video content. Recent editions have sought to place greater emphasis on clinical applicability while maintaining a solid foundation in basic science. As with any educational program, it reflects the experience of its authors. As its faculties change and medicine progresses, new viewpoints emerge on controversial subjects and techniques. Not all alternate approaches can be included in this series; as with any educational endeavor, the learner should seek additional sources, including Academy Preferred Practice Pattern Guidelines.

The BCSC faculty and staff continually strive to improve the educational usefulness of the course; you, the reader, can contribute to this ongoing process. If you have any suggestions or questions about the series, please do not hesitate to contact the faculty or the editors.

The authors, editors, and reviewers hope that your study of the BCSC will be of lasting value and that each Section will serve as a practical resource for quality patient care.
Objectives

Upon completion of BCSC Section 4, *Ophthalmic Pathology and Intraocular Tumors*, the reader should be able to

- describe a structured approach to understanding major ocular conditions based on a hierarchical framework of topography, disease process, general diagnosis, and differential diagnosis
- list the steps for handling ocular specimens for pathologic study, including obtaining, dissecting, processing, and staining tissues
- explain the basic principles of special procedures used in ophthalmic pathology, including immunohistochemistry, flow cytometry, molecular pathology, and diagnostic electron microscopy
- discuss the types of specimens, processing, and techniques appropriate to the clinical situation
- describe the histopathology of common ocular conditions
- discuss the relationship between clinical and pathologic findings in various ocular conditions
- list the steps in wound healing in ocular tissues
- state current information about the most common primary tumors of the eye
- identify those ophthalmic lesions that indicate systemic disease and are potentially life threatening
- discuss genetic information that would be useful to provide to families affected by retinoblastoma
- describe current treatment modalities for ocular tumors in terms of patient prognosis and ocular function